重型与中间型β地中海贫血的妊娠结局及铁状态:系统综述与荟萃分析
该系统综述纳入15项研究(429名参与者、684次妊娠),评估重型地中海贫血(TM)与中间型地中海贫血(TI)的母婴结局及妊娠对铁稳态的影响。荟萃分析显示TI血栓风险3.7%高于TM的0.92%,TM孕产妇死亡率为3.7%;TM妊娠期红细胞需求显著增加(从102增至139 ml/kg/年,P=0.001),铁蛋白和肝铁浓度显著升高,心肌T2*下降。
要点
- TI血栓风险3.7%高于TM的0.92%,与孕前相比无变化。
- TM妊娠期红细胞需求从102增至139 ml/kg/年(P=0.001)。
- 妊娠期铁蛋白TM升高1005 ng/mL、TI升高332 ng/mL(P<0.0001)。
核心结论
- 这些发现强调妊娠和分娩期间铁相关心肌病的孕产妇风险升高,并强调心脏监测和产后恢复螯合治疗的重要性。
研究设计与样本
- 系统综述与荟萃分析,纳入15项研究,共429名参与者、684次妊娠。
主要发现
- TI血栓风险为3.7%,高于TM的0.92%,与孕前相比无变化。
- 早期年份心力衰竭风险TM为1.6% vs TI为1.1%,TM孕产妇死亡率为3.7%,但在当前管理下这些风险罕见。
- TM妊娠中妊娠期糖尿病和子痫前期发生率分别为3.9%和11.3%。
- 剖宫产率TM为83.9% vs TI为67%。
- TM与TI之间死产、小于胎龄儿或早产发生率无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advancements in orally bioavailable iron chelators and MRI methods have improved life expectancy and reproductive potential in thalassemia major (TM) and thalassemia intermedia (TI). Pregnancy is associated with adverse maternal and neonatal outcomes, frequency of which has not been well delineated. This systematic review aims to provide risk estimates of maternal and fetal outcomes in TM and TI and explore pregnancy's impact on iron homeostasis. Fifteen studies (429 participants, 684 pregnancies) were included. Meta-analysis revealed a higher thrombosis risk in TI (3.7%) compared to TM (0.92%), unchanged from prepregnancy. Heart failure risks in the earlier years appeared similar (TM 1.6% vs TI 1.1%), and maternal mortality in TM was 3.7%, but with current management, these risks are rare. Gestational diabetes and pre-eclampsia occurred in 3.9% and 11.3% of TM pregnancies, respectively. Caesarean section rates were 83.9% in TM and 67% in TI. No significant difference in stillbirth, small for gestational age neonates, or preterm birth incidence between TM and TI was observed. In TM pregnancies, red cell requirements significantly increased (from 102 to 139 ml/kg/year, P = 0.001), and 70% of TI pregnancies required blood transfusions. As expected, increased transfusion alongside chelation cessation led to a significant increase in serum ferritin during pregnancy (TM by 1005 ng/mL; TI by 332 ng/mL, P < 0.0001). Deterioration in iron status was further reflected by an increase in liver iron concentration (from 4.6 to 11.9 mg/g dry weight, P < 0.0001), and myocardial T2-star (T2∗) magnetic resonance imaging decreased (from 36.2 ± 2.5 ms to 31.1 ms) during pregnancy. These findings emphasize the elevated maternal risk of iron-related cardiomyopathy during pregnancy and labor, stressing the importance of cardiac monitoring and postpartum chelation therapy resumption.
引用
- Vlachodimitropoulou E, Mogharbel H, Kuo KHM, et al. Pregnancy outcomes and iron status in β-thalassemia major and intermedia: a systematic review and meta-analysis. Blood Adv. 2024. PMID: 38181780. doi:10.1182/bloodadvances.2023011636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。